>BIOD – what I thought was more troublesome commercially was the injection site pain due, the much higher volume and the formulation stinks as it need to be refrigerated/reconcentrated, so no pens.<
Also a longer needle, which may be one reason (in addition to higher injection volume) for the injection-site pain.
>BIOD – There actually is a lot of interest in the diabetes community for this…<
I guess I don’t see the attraction from a business standpoint of an enhanced formulation of a product—ordinary insulin—that is in a state of steady and irreversible decline.
What is the allure of BIOD’s reformulation (and similar products from other companies) versus an insulin analog or cocktail of analogs? T.i.a.
Market Data 
Markets 
AI
